INR 5,829
CLICK TO EDIT MASTER TITLE STYLE KEY HIGHLIGHTS Overall Revenue EBITDA Margin R&D Investment2 INR 5,829 Cr 6% overall YoY growth 12% Ex-covid YoY growth Overall 22.3% Adj. margin1 ~24% INR 335
6%
MASTER TITLE STYLE KEY HIGHLIGHTS Overall Revenue EBITDA Margin R&D Investment2 INR 5,829 Cr 6% overall YoY growth 12% Ex-covid YoY growth Overall 22.3% Adj. margin1 ~24% INR 335 Cr 22
12%
HIGHLIGHTS Overall Revenue EBITDA Margin R&D Investment2 INR 5,829 Cr 6% overall YoY growth 12% Ex-covid YoY growth Overall 22.3% Adj. margin1 ~24% INR 335 Cr 22% YoY growth 5.8% of ove
22.3%
Margin R&D Investment2 INR 5,829 Cr 6% overall YoY growth 12% Ex-covid YoY growth Overall 22.3% Adj. margin1 ~24% INR 335 Cr 22% YoY growth 5.8% of overall revenue BUSINESS UNIT-WISE REVE
24%
2 INR 5,829 Cr 6% overall YoY growth 12% Ex-covid YoY growth Overall 22.3% Adj. margin1 ~24% INR 335 Cr 22% YoY growth 5.8% of overall revenue BUSINESS UNIT-WISE REVENUE & YOY GROWTH On
INR 335
R 5,829 Cr 6% overall YoY growth 12% Ex-covid YoY growth Overall 22.3% Adj. margin1 ~24% INR 335 Cr 22% YoY growth 5.8% of overall revenue BUSINESS UNIT-WISE REVENUE & YOY GROWTH One-India N
22%
6% overall YoY growth 12% Ex-covid YoY growth Overall 22.3% Adj. margin1 ~24% INR 335 Cr 22% YoY growth 5.8% of overall revenue BUSINESS UNIT-WISE REVENUE & YOY GROWTH One-India North Am
5.8%
growth 12% Ex-covid YoY growth Overall 22.3% Adj. margin1 ~24% INR 335 Cr 22% YoY growth 5.8% of overall revenue BUSINESS UNIT-WISE REVENUE & YOY GROWTH One-India North America SA Private
15%
E REVENUE & YOY GROWTH One-India North America SA Private International Markets 6% (Overall) 15% (Ex-covid) YoY growth in INR terms Robust traction in core portfolio across therapies and busin
25%
in INR terms Robust traction in core portfolio across therapies and business segments $ 179 Mn 25% YoY growth in $ terms Differentiated portfolio unlocking with the launch of Lenalidomide and mar
1%
anreotide 505b2 Note: 1. Excludes impact of covid inventory charge|2. Opex including depreciation 1% 28% $ 96 Mn YoY in ZAR terms QoQ growth in ZAR terms Recovery on track; double digit sequenti
28%
otide 505b2 Note: 1. Excludes impact of covid inventory charge|2. Opex including depreciation 1% 28% $ 96 Mn YoY in ZAR terms QoQ growth in ZAR terms Recovery on track; double digit sequential gr